mesothelioma, ovarian, and lung adenocarcinoma. Therefore, it could potentially be used as a tumor marker or as an antigenic target of vaccines. 4 No effective therapeutic modalities exist for malignant mesothelioma apart from surgical resection in 10% to 15% of the patients. In the advanced disease, chemotherapy has a marginal effect and the prognosis is extremely poor. 5 Hence, there is an urgent need for new and more effective therapies. Oncolytic adenoviruses are promising immunotherapeutic agents for advanced and treatment-refractory cancer patients. Their antitumor activity is based on the direct lysis of cancer cells and the induction of systemic antitumor immunity. [6] [7] [8] [9] Oncolysis leads to the release of tumor epitopes that can be processed by antigen-presenting cells [10] [11] [12] [13] [14] [15] [16] [17] [18] to activate antigen-specific CD4+ and CD8+ T-cell responses. Immunogenic cell death leads to changes in cell surface structure, such as exposure of calreticulin in the outer plasma membrane and subsequent release of high-mobility group box 1 protein and adenosine triphosphate. 19 Activated CD8+ T-cells can expand into cytotoxic effector cells and infiltrate tumors where they mediate antitumor immunity after antigen recognition.
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
mediates antitumor effects by mobilizing and maturing dendritic cells as well as increasing the activity of cytotoxic T-cells. [15] [16] [17] Systemic use of recombinant GM-CSF is associated with welldescribed harmful toxicities. Also, this route of administration may not result in an adequate local concentration of GM-CSF in the tumors. 20 Thus, engineering the viral genome with the gene encoding GM-CSF reduces the risk of toxicities, ensuring desired local levels of GM-CSF to improve the induction of antitumor immunity.
Ranki et al 16, 17 reported the results of a Phase I study (NCT01598129) in which ONCOS-102 (Ad5/3-Δ24-GM-CSF) was well tolerated and induced local and systemic CD8+ T-cell immunity in patients with treatment-refractory and immune-cell poor solid tumors.
They also observed an upregulation of programmed death ligand 1 (PD-L1) after treatment with ONCOS-102, suggesting that combination of ONCOS-102 with checkpoint inhibitors, including PD-1/PD-L1 inhibitors, could be beneficial against such refractory tumors.
We have earlier reported synergistic antitumor efficacy of ONCOS-102 in combination with standard of care chemotherapy (pemetrexed, cisplatin, and carboplatin) in a xenograft BALB/c model of human malignant mesothelioma. The synergism observed in this preclinical study gives hope for combinations of ONCOS-102 with first-line chemotherapy in patients suffering from malignant mesothelioma. 19 In this study, we show the induction of T-cells specific for mesothelin, hexon, and E1A antigens after the treatment of mesothelioma-bearing BALB/c mice with ONCOS-102 and the effectiveness of the interferon (IFN)-γ ELISPOT in detecting this response. according to good laboratory practice and stored at −80°C until use.
| MATERIALS AND METHODS

| Materials and reagents
| Mesothelioma xenograft model
All animal experiments were approved by the Ethics Committee for 
| IFN-γ ELISPOT
At endpoint (day 20), spleens were harvested from untreated (phosphate-buffered saline) and ONCOS-12-treated BALB/c mice.
Splenocytes were isolated to determine counts of T-cells responding to mesothelin, human adenovirus 5 E1A, and hexon peptides by secretion of IFN-γ. Harvested splenocytes were stimulated with peptide pools of the complete murine mesothelin protein sequence, human adenovirus 5 E1A, and hexon proteins. IFN-γ production by T-cells was evaluated by using IFN-γ ELISPOT (Abcam, Cambridge, UK). A single-cell suspension of 2.5 × 10 5 splenocytes/well was plated in RPMI medium including 200 ng of peptide. After incubating overnight at 37°C and 5% CO 2 , plates were washed and stained with biotinylated anti-mouse IFN-γ and incubated for 2 hours, followed by streptavidin conjugate enzyme. The spots were counted using the ELISpot Reader (AID, Strasberg, Germany).
| Statistical analysis
Statistical significance was analyzed by using the Mann-Whitney test.
All statistical analysis, calculations and tests were performed using GraphPad Prism 7 (GraphPad Software, San Diego, CA). Results are presented as mean ± standard deviation. All P values were 2 sided and considered statistically significant when ≤.05. T-cell epitopes that could be used to prime antigen-specific T-cells and challenge adoptively transferred T-cells in vivo. These epitopes span conserved regions of the hexon protein and would be useful to monitor immune response before and after immunotherapy. 24 As the capsid of ONCOS-102 contains hexon protein, which plays an important role in virus entry into cells, and E1A protein, which binds to pRb/p300 family of histone acetyltransferases and induces p53-dependent apoptosis in cancer cells 5 ; they were used to stimulate the splenocytes in ELISPOT.
Mice treated with the virus generated specific T-cells against hexon and E1A antigen, as can be seen in Figure 1 , in which the signal was detected from only ONCOS-102-treated mice. This is not surprising as viral capsid components such as hexon, 22 penton, and 
